drugset / Trial / NCT00234871

Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)

NCT00234871

Phase 4 Completed 357 enrolled Abbott
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy

Timeline

Start
2004-01
Primary completion
2005-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg
Comparator Benazepril Unknown 20 mg
Comparator Verapamil Other / unclassified 240 mg
Comparator trandolapril Small molecule 4 mg